Financings Of The Fortnight: Recent IPO Slowdown Not Necessarily A Harbinger For A Bad 2014
This article was originally published in The Pink Sheet Daily
Series A financing volume is up in recent years, suggesting that 2014 will be a strong year for biotechs opting to go public. Plus financing news from Atara Biotherapeutics, Crescendo Biologics, Acucela and TetraLogic.
You may also be interested in...
After a bit of a lull since September, there are seven biotechnology IPOs slated to get out in the next few weeks. But they are entering a tougher market than earlier in 2013, and some may not be quite the same quality.
“Early and primitive” is a term frequently used to describe drug development for dry AMD in discussions with experts. Several companies have brought products to Phase II trials, but none has met the efficacy endpoints. A new crop of start-ups is trying, driven by the huge unmet demand and emerging science.
Pipeline Watch is a weekly snapshot of selected late-stage clinical trial events and approvals announced by pharmaceutical and biotech companies at medical and industry conferences, in financial and company presentations, and in company releases and statements.